Loading..
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in brief
    • Vision
    • History
    • Organisation
    • New Partnerships
  • Our Science
    • Resolving Inflammation
    • Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The AP1189 Development Program
    • Rheumatoid Arthritis
    • Membranous Nephropathy
    • Virus Induced Respiratory Insufficiency
    • Ongoing clinical studies
  • Investors
    • Listing Nasdaq 2022
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
      • Nomination Committee 2023
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact

Press Releases

All releases
    • Regulatory
    • Non Regulatory
2020
  • 2023
  • 2022
  • 2021
  • 2019
  • 2018
  • 2017
  • 2016
  • All years
November 9, 2020
Regulatory

SynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis

November 6, 2020
Regulatory

Bulletin from the extraordinary shareholders’ meeting in SynAct Pharma AB

October 20, 2020
Regulatory

Notice of extraordinary shareholders’ meeting in SynAct Pharma AB

October 20, 2020
Regulatory

Shareholders of SynAct Pharma proposes Uli Hacksell as new board member

October 19, 2020
Regulatory

SynAct Pharma terminates agreement for liquidity providing

October 12, 2020
Regulatory

English version of PR published 20201012 at 07.33AM     SynAct Pharma completes part 1 of clinical phase II study with AP1189 in Rheumatoid Arthritis

September 23, 2020
Regulatory

Swedish version of press release published earlier today. SynAct Pharma initierar fas II-studie med AP1189 för behandling av ARDS i COVID-19-patienter

September 23, 2020
Regulatory

SynAct Pharma Initiates Phase II Study with AP1189 for the Treatment of ARDS in COVID-19 Patients

September 3, 2020
Regulatory

SynAct Pharma informs that the recruitment to part 1 in the Clinical Phase II study with AP1189 in Rheumatoid Arthritis is completed

September 1, 2020
Regulatory

SynAct Pharma Informs about Termination of Coverage Agreement with Redeye

August 28, 2020
Regulatory

SynAct Pharma Initiates RESOVIR: Scientific and clinical Collaboration to Explore AP1189 in Viral Infections

July 27, 2020
Regulatory

Synact Pharma announces outcome in the exercise of warrants, will receive approximately MSEK 32.4

July 15, 2020
Regulatory

SynAct Pharma AB: Update on SynAct Pharma´s Clinical Phase II study with AP1189 in Rheumatoid Arthritis

June 30, 2020
Regulatory

SynAct Pharma announces that the exercise period for warrants of the TO 2 series will start on July 1, 2020

June 29, 2020
Regulatory

SynAct Pharma has initiated the Phase II clinical study with AP1189 in Nephrotic Syndrome

June 25, 2020
Regulatory

SynAct Pharma’s Board of Directors and management sign subscription commitment for warrant exercise of series TO 2

June 2, 2020
Regulatory

SynAct Pharma´s clinical trial application for AP1189 in Nephrotic Syndrome approved by the Danish Medical Agency

May 25, 2020
Regulatory

SynAct Pharma files patent application for combination of AP1189 and Methotrexate for treatment of RA and other arthritic diseases

May 5, 2020
Regulatory

SynAct presents initial data from the first part of the Phase II study within RA and gives an update on its progression

April 3, 2020
Regulatory

SynAct Pharma applies for patent for AP1189 within COVID-19

April 2, 2020

BIOSTOCK: Synact Pharma on expansion into Covid-19 (also available in Swedish)

March 31, 2020
Regulatory

SynAct Pharma submits clinical trial application for AP1189 in Nephrotic Syndrome

March 31, 2020
Regulatory

Translation – UK version of Swedish press release – published 08.00 AM. today – SynAct Pharma investigates the possibility of AP1189 as additional therapy in hospitalized patients with COVID-19

  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • LinkedIn

Subscribe